Abstract
Introduction
Breast, cervical, colorectal, and prostate cancers cause significant health burdens in the United States. In 2013, these cancers accounted for nearly 40% of all new cancer diagnoses and about 20% of cancer deaths (1). Screening is a primary tool for early detection and reduction in deaths from cancer. Examining screening disparities -differences in receipt of screening among population subgroups -over time offers the opportunity to monitor cancer screening successes and advancement toward Healthy People 2020 goals (2).
Healthy People 2020 objectives for use of cancer screening tests include increasing the proportion of women aged 21 to 65 screened for cervical cancer, women aged 50 to 74 screened for breast cancer, and men and women aged 50 to 75 screened for colorectal cancer (2). Healthy People 2020 objectives also include reducing prostate cancer deaths (2). Routine prostate-specific antigen (PSA) testing was not recommended (3) at the time of this analysis; however, test use was common (4).
The National Health Interview Survey (NHIS) has been used for more than 30 years to measure the nation's progress toward meeting Healthy People objectives for cancer screening (2). This article examines the sex-specific prevalence of use of screening tests for cervical, breast, colorectal, and prostate cancers reported by adults in NHIS 2015. Adjusting for sociodemographic characteristics and access to care factors, we assessed differences in screen-ing among underserved groups. We examined screening trends from NHIS for 2000, 2003, 2005, 2008, 2010, 2013 , and 2015, testing for possible interactions to assess whether use of cancer screening tests in the United States changed overall and for subgroups over those time periods. We assessed progress toward reducing screening disparities, which should aid in decreasing the overall burden of cancer in the United States. This information can be used to assess the persistent unmet needs of underserved groups and to set priorities for interventions to reduce disparities.
Methods
National Health Interview Survey NHIS (www.cdc.gov/nchs/nhis/index.htm), a nationally representative cross-sectional sample of the civilian, noninstitutionalized, US population, is the principal source of information on the health of the nation. The survey excludes residents of long-term care facilities, people on active duty with the Armed Forces (their dependents are included), people incarcerated in the prison system, and US citizens living in foreign countries. NHIS collects sociodemographic and health information via in-person interviews for each participating household. Interviews are conducted by US Census Bureau. The NHIS annual questionnaire includes periodic supplements that cover one or more sets of questions on specific health topics, including cancer screening.
NHIS Cancer Control Supplements were fielded in 2000, 2003, 2005, 2008, 2010, 2013, and 2015 . The final sample adult response rates ranged from 55.2% (2015) to 74.2% (2003) (5). Respondents were asked questions regarding Papanicolaou (Pap) tests and hysterectomy, mammograms, PSA tests, and endoscopic exams and fecal occult blood tests (FOBT) screening for colorectal cancer. For each type of cancer screening, respondents who reported having a test were asked when they had the most recent test.
We used NHIS 2015 data to estimate prevalence of cancer screening. Our definitions of recent screening are consistent with US Preventive Services Task Force (USPSTF) recommendations in effect in 2015. We defined recent breast cancer screening as having received a mammogram within 2 years, recent cervical cancer screening as having a Pap test within 3 years (among women without hysterectomy), and recent colorectal cancer screening as either FOBT within the past year, or flexible sigmoidoscopy within 5 years and FOBT within 3 years, or colonoscopy within 10 years. We used NHIS data from the 2000 through 2015 cycles to describe trends in breast, cervical, and colorectal cancer screening. We examined routine PSA testing in the past year among men aged 50 or older to examine change in use following the 2012 USPSTF guideline revision that recommended against routine screening using PSA (3).
Statistical analysis
We calculated the proportion of respondents who reported receiving a recent screening test for each type of cancer after adjustment for covariates. We used multivariable logistic regression models to estimate the adjusted association between sociodemographic and access-to-care factors for each type of screening. Independent variables were age, race/ethnicity, education, annual income as a percentage of the federal poverty level, length of US residency, health insurance status and type, having a usual source of care, and consulting a doctor in the past 12 months. Among women, we included consulting a gynecologist in the past 12 months. From logistic regression results, we estimated predictive margins, which are adjusted proportions of screened individuals (6). The predictive margin is computed for a specific group (eg, type of health insurance) as the sample weighted average of the predicted responses from the logistic regression model, assigning each individual in the sample to that group membership while keeping all other covariates unchanged.
Using combined data from all NHIS years, we used multivariable logistic regression models to assess trends over time. Survey year was included as an independent variable, adjusting for the covariates described above. We assessed interactions between survey year and usual source of care or insurance type by including the appropriate product terms in the logistic regression models. We dropped nonsignificant interactions from the final model by using backward elimination (setting 2-sided α = 0.05). We present figures depicting the time trends as predictive margins. Statistical testing was based on the Wald F statistic for jointly testing that all regression coefficients for a given covariate were equal to zero. We used 95% confidence intervals (CIs) around the predictive margins to allow for informal pairwise comparisons, although examining overlap between CIs to determine significance is a conservative method. The National Center for Health Statistics imputed missing income data by using multiple imputation. All analyses were performed by using SAS version 9.3 (SAS Institute Inc) and SUDAAN version 11.0.1 (RTI International) to account for the complex sampling design and to allow for sample weighted estimation. All hypothesis tests were considered significant if the 2-sided P value unadjusted for multiple comparisons was less than .05.
Results
In 2015, most women reported having recent screening for cervical, breast, and colorectal cancer (Table 1) . However, estimates for all tests, for both women and men, fell short of Healthy People 2020 targets (Figure 1) . (Table 3) . Reporting recent screening was lowest among men aged 50 to 64 (PM, 57.4; 95% CI, 55.0-59.7), men with less than a high school education (PM, 53.9; 95% CI, 48.4-59.3), men with an annual income less than 139% of the federal poverty level (PM, 55.2; 95% CI, 50.7-59.7), men without a usual source of health care (PM, 42.2; 95% CI, 35.5-49.1), uninsured men (PM, 49.0; 95% CI, 40.8-57.2), and men who had not consulted a doctor in the past 12 months (PM, 47.8; 95% CI, 44.2-51.5).
Prostate-specific antigen test
Among men aged 50 years or older, 35.8% (95% CI, 34.2-37.4) reported having a PSA test in the past year (Table 3) . Reporting a recent PSA test was lowest among men aged 50 to 64 years (PM, 30.3; 95% CI, 28.3-32.4), men with less than a high school education (PM, 26.9; 95% CI, 22.8-31.3), men with annual income less than 139% of the federal poverty level (PM, 30.8; 95% CI, 26.6-35.4), men with no usual source of health care (PM, 20.2; 95% CI, 13.7-28.6), uninsured men (PM, 26.0; 95% CI, 17.8-36.2), non-Hispanic Asian men (PM, 16.8; 95% CI, 11.6-23.8), and men who had not consulted a doctor in the past 12 months (PM, 18.3; 95% CI, 15.3-21.8). Among men, colorectal cancer screening use increased significantly for all men and over time among all insurance groups, but varied by insurance type (Figure 2, D) . From 2000 through 2010, the increase was larger among men with private insurance (27.2%) than other insurance groups. The rate then declined in 2013 before increasing again in 2015 for an overall increase of 28.5%. The increases among men with public insurance (26.5%) and among the uninsured (26.3%) were more linear during the period. Use of an annual PSA test declined significantly (9.2%) from 2008 through 2013 but remained stable from 2013 through 2015, dropping 4.5% overall ( Figure 2E ). No significant interactions between sociodemographic characteristics or access to care and having a recent PSA test were observed.
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Discussion
The 2015 NHIS findings show that use of cancer screening tests for cervical, breast, and colorectal cancer remained below Healthy People 2020 targets. Significant variation in test use by sociodemographic characteristics and access to care factors remained after adjustment. For all tests studied, the lowest screening rates were generally associated with having no usual source of care, no insurance, not having seen a physician in the past 12 months, and identifying as non-Hispanic Asian. Younger age, lower income, and fewer years of education were also consistently associated with lower prevalence of screening for both men and women. Examination of trends adjusted for these factors showed a persistent screening disparity over time for those uninsured or with no usual source of care. Patterns of disparities in screening test use found among population subgroups in 2015 were consistent with those found in previous cycles of NHIS (7) (8) (9) . A striking exception was that non-Hispanic white women were less likely than non-Hispanic black women or Hispanic women to obtain Pap tests or mammograms in 2015.
Only use of colorectal cancer screening increased in 2015 (10) . Although rates improved for most groups examined, screening for colorectal cancer was lowest among uninsured women and men (women, 45%; men, 49%), those with no usual source of care (women, 46%; men, 42%), those with no doctor consult in the past 12 months (women, 49%; men, 48%), and non-Hispanic Asians (women, 55%; men, 51%). Colorectal cancer screening is effective and can prevent cancer; however, even in 2015, when rates for Pap tests and mammography were 80% and 70%, respectively, rates for colorectal cancer screening were just above 60%. Focused PREVENTING CHRONIC DISEASE VOLUME 15, E97 PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY
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public health efforts to promote colorectal cancer screening may have helped increase rates over the past 10 years. However, sustained efforts will be necessary to increase awareness of the need for screening, continued expansion of insurance coverage, and use of electronic medical records with automatic reminders to patients and physicians (11) for further increases in test use, particularly among those subgroups with the lowest use.
Pap test and mammography rates showed slight declines in use from 2000 to 2015, and overall measures remained below national targets, especially for specific subgroups of women. Though Pap test screening exceeded 80%, and mammography exceeded 70%, test rates were lower than the Healthy People 2020 targets of 93% for Pap tests and 81% for mammography (2,9). In 2017, Watson and colleagues estimated that in 2015, 14 million women aged 21 to 65 had not had a Pap test in the past 3 years (12) . To reverse the downward trend and improve outreach to those rarely or never screened, educational and promotional interventions or information dissemination efforts will be needed, and accurate monitoring will be important. Enhanced efforts are needed to increase screening among underserved groups.
The prevalence of use of the PSA test dropped 5 percentage points, from 42.6% in 2005 to 37.3% in 2015, extending earlier trends documenting reduction in test use. In 2012, USPSTF recommended against routine PSA testing and since there has been a drop in the test being offered by physicians and used by patients (13, 14) consistent with our findings. In 2015, Drazer and colleagues reported the largest decreases were observed among white men and men aged 50 and older (13); however, screening still occurred in 36% of men. Approximately one-third of men older than 75 with a life expectancy of less than 10 years were screened in 2013, although screening is never recommended for such patients. A 2017 update to the 2012 USPSTF PSA screening recommendation (15) recommends that men aged 55 to 69 years discuss the potential benefits and harms of PSA screening with their clinician and incorporate their values and preferences in the screening decision. The 2017 update also recommends men aged 70 and older should not be screened, and men at higher risk of prostate cancer, such as African American men or those with a family history, should consult their clinician about the appropriateness of considering screening before age 55. Therefore, it will be important to continue to monitor test use to determine if prevalence of testing rises following the 2017 update.
The cancer screening objectives for Healthy People 2020 provide targets for monitoring cancer incidence, mortality, and survival. Our analysis of the 2015 NHIS showed that halfway through the Healthy People 2020 decade, estimates for use of cervical, breast, and colorectal cancer screening tests are well below Healthy People 2020 targets. An estimated 24.4 million people would need to be screened in the United States to achieve the National Colorectal Cancer Roundtable target of screening 80% of age-appropriate individuals by 2018 (16), including 3.9 million people expected to reach screening age from 2015 through 2018.
One approach to improving screening use across all subgroups would be for physicians to recommend screening to all age-appropriate patients (17) , including traditionally underserved groups (low-income, uninsured, low acculturation or assimilation, Hispanic, and non-Hispanic Asian) (18, 19) . Although having insurance coverage does not ensure doctor visits, universal health insurance coverage and universal access to a usual source of health care would likely increase physician access to all groups to encourage screening. Although it would be optimal for physicians to recommend screening to less acculturated and uninsured Hispanics and Asians and in their own languages (20, 21) , studies suggest that physician enthusiasm and outreach with tailored or innovative strategies to educate and inform (22) may increase knowledge and intention to screen among underserved groups, such as Hispanics, Asians, the uninsured, and the less educated. Culturally tailored strategies may be particularly effective for Asians disproportionately affected by discordance in patient-provider language and gender (provider and patient being of different genders) (22,23). More research and evaluation of public health campaigns designed to increase screening among underserved groups are needed.
Evidence-based, multicomponent interventions have potential to substantially increase screening rates among population groups with low screening rates (24,25). Efforts that result in better continuity and coordination of care, such as community-based patient navigation programs, may be particularly useful. Care coordination is a key strategy with potential to improve health care system effectiveness, safety, and efficiency. Well-designed, targeted coordination efforts can improve patient, provider, and payer outcomes (26). The Community Preventive Services Task Force findings suggest that multicomponent interventions that increase community demand and access along with increasing provider delivery of services show the greatest screening effects (27). Combined with provision of appropriate follow-up care and treatment, these interventions may improve health for the underserved.
Our study had limitations. Survey data were self-reported and not confirmed by medical record review. Data did not distinguish diagnostic tests from screening and may have overestimated test use for screening purposes. In addition, American Indian, Alaska Native, and Pacific Islander samples were too small to analyze separately and were included in a "non-Hispanic other" group; limiting our knowledge about these subgroups. Monitoring screening among all these groups is essential to determine what allocation of resources and efforts is necessary to increase their screening PREVENTING CHRONIC DISEASE VOLUME 15, E97 PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY
www.cdc.gov/pcd/issues/2018/17_0465.htm • Centers for Disease Control and Preventionparticipation. Lastly, beginning in 2010, NHIS asked separate questions for each type of endoscopy (sigmoidoscopy vs colonoscopy). Before 2010, respondents were asked which endoscopy type was the most recent test. If the most recent test was a sigmoidoscopy that occurred within 10 years but did not meet recommendations, we assumed that the sigmoidoscopy was not preceded by a colonoscopy within 10 years, and that screening was not up to date. Although this may underestimate screening slightly, having a sigmoidoscopy following a recent colonoscopy is likely to be rare.
Given the rate of change between 2000 and 2010, accelerated uptake is needed to reach Healthy People 2020 targets for screening for cervical, breast, and colorectal cancers. Again in 2015, the uninsured and those with no usual source of care were least likely to have received a screening test within recommended timelines. Continued efforts are needed to reduce structural barriers for access to medical care and to increase physician contact to increase the proportion of people counseled and participating in cancer screening, particularly among underserved subgroups. In addition to more consistent physician recommendation, screening promotion efforts for all tests directed at patients need to identify and address barriers among Asians, those without a usual source of care, and the uninsured. Culturally and linguistically appropriate and targeted interventions have been shown to maintain high rates of Pap test and mammography screening and to continue to increase colorectal cancer screening (28-30). Appropriate diagnosis, timely follow-up, and effective treatment will help to make inroads toward reducing overall cancer burden and improving health equity in cancer outcomes for all. Continued monitoring is critical to learn how screening rates compare with Healthy People 2020 targets, and it is important to adjust for sociodemographic factors because of changes in insurance coverage and racial/ethnic composition in the population over time. PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY
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